In the last years, the increased understanding of MCL cell biology led to the use of different therapeutic agents active against this lymphoma, including the proteasome inhibitor bortezomib (BTZ) [15–17], or mammalian target of rapamycin (mTOR) antagonists such as everolimus and temsirolimus [18, 19]. Here, MTOR is linked to lymphoma.